Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wan-Ju Annabelle Lee has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Edward Chia-Cheng Lai

    School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine National Cheng Kung University Tainan Taiwan

    5 shared publications
  • I -C Liao

    Department of Pathology, Chi Mei Medical Center, Tainan 710, Taiwan

    3 shared publications
  • Shih-Chieh Shao

    School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    3 shared publications
  • Shih-Chieh Shao

    School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    3 shared publications
  • Swu-Jane Lin

    University of Illinois Chicago, Chicago, Illinois, USA

    3 shared publications
  • Tzu-Chi Liao

    Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    3 shared publications

Latest Publications

  • Open Access

    Comparison of adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema: A global network study

    by Wan-Ju Annabelle Lee, Daniel Hsiang-Te Tsai, Michael Chun-Yuan Cheng, Yu-Shiuan Lin, Chia-Yi Lee, Shih-Chieh Shao, Edward Chia-Cheng Lai

    Purpose: Patients with diabetic macular oedema (DMO) are susceptible to renal injury, raising the risks of acute kidney injury (AKI) and end-stage renal disease (ESRD) associated with anti-VEGF therapies. We aimed to compare the risks of AKI and ESRD between aflibercept and ranibizumab in DMO patients, focusing on AKI and ESRD in conjunction with all-cause mortality. Methods: A target trial emulation using the TriNetX Global Collaborative Network included adult patients with DMO who initiated treatment with aflibercept or ranibizumab in routine clinical practice. Ranibizumab exposure reflected real-world use and included both approved dosages. Patients with pre-existing ESRD or chronic kidney disease stage 5 were excluded. Propensity score matching was applied to balance demographics, comorbidities, medication use, and laboratory parameters. Time-to-event analyses were performed for AKI, ESRD, and all-cause mortality. Sensitivity analyses included application of a minimum 7-day latency window after treatment initiation to address potential temporality bias. Results: After matching, 3411 patients were included in each treatment group (mean age, 64.0 ± 12.4 years; 51.5% male). During follow-up, aflibercept was not associated with an increased risk of AKI (hazard ratio [HR]: 0.97, 95% confidence interval [CI]: 0.89-1.06), ESRD (HR: 0.95, 95% CI: 0.83–1.09), or all-cause mortality (HR: 0.99, 95% CI: 0.89–1.10), when compared with ranibizumab. Results were consistent across subgroup and sensitivity analyses, including analyses incorporating a 7-day latency window with an HR of 1.08 (95% CI: 0.94–1.24) for AKI, and 0.89 (95% CI: 0.76–1.04) for ESRD. Conclusions: In this multinational, real-world study, aflibercept and ranibizumab demonstrated comparable risks of AKI, ESRD and mortality among patients with DMO after adjustment for measured confounders. Given the observational design, real-world dose heterogeneity, and limitations in detailed treatment-timing data, these findings should be interpreted with caution.


  • Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications

    by Wan-Ju Annabelle Lee, Daniel Hsiang-Te Tsai, Shih-Chieh Shao, Edward Chia-Cheng Lai

    This multi-institutional real-world study evaluated the incidence of intraocular inflammation (IOI) following faricimab treatment across major retinal diseases. The study reviewed records of adults treated with faricimab between January 2022 and April 2025 and classified them into four disease cohorts: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and polypoidal choroidal vasculopathy (PCV). Patients with a recent history of IOI were excluded. In total, 7784 patients were analyzed, including 4085 with nAMD, 1456 with DME, 1057 with RVO, and 1166 with PCV. Mean ages varied by disease group, ranging from 65.5 years in DME to 75.6 years in nAMD, and more than half of all patients had prior intravitreal anti-VEGF therapy. Within 180 days of treatment initiation, the incidence of new-onset IOI was 0.54% with nAMD, 1.24% with DME, 1.23% with RVO, and 1.03% with PCV. Overall, IOI risk ranged from approximately 0.5 to 1.2%, with higher rates observed among patients with DME and RVO. These findings highlight the importance of ongoing pharmacovigilance as newer retinal therapeutics enter clinical practice, and they provide timely evidence to support safety monitoring in real-world ophthalmology settings.


  • Open Access

    Seeing the unseen: A case series of intracranial mass lesions initially presenting with visual disturbances

    by Huai-Wen Hsu, Tim Yi-Ting Chen, Shu-Chun Kuo, Wan-Ju Annabelle Lee

    This study aimed to characterize the clinical presentation, ophthalmologic findings, and final diagnoses of patients with primary intracranial mass lesions who initially presented with visual symptoms. We conducted a retrospective observational case series at the Neuro-ophthalmology Department of Chi Mei Medical Center, Taiwan, analyzing adult patients who presented with visual disturbances between January 2021 and August 2023 and were subsequently diagnosed with intracranial mass lesions. Demographic characteristics, ophthalmologic findings, imaging results, treatment modalities, and visual outcomes were analyzed. Thirteen patients were included (six men; mean age: 45.2 ± 13.1 years). Blurred vision (61.5%) was the most frequent presenting symptom. Visual field defects (76.9%) and optic disc pallor (53.9%) were common findings. Pituitary adenoma was the most predominant tumor type (38.5%). The results indicate that visual symptomatology may represent an early manifestation of primary intracranial mass lesions. Prompt neuroimaging and multidisciplinary management are essential for achieving timely diagnosis and optimal clinical outcomes.

  • Open Access

    Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

    by Yung-Yu Chu, Cheng-Hao Sung, Yu-Shiuan Lin, Chung-Han Ho, Yi-Chen Chen, Wan-Ju Annabelle Lee, Shu-Chun Kuo

    Importance: The relationship between atopic dermatitis (AD) and pediatric uveitis may be underexplored, warranting large-scale, multicenter studies.Objective: To evaluate the risk of pediatric uveitis among children with early-onset AD compared with a matched control population.Design, Setting, and Participants: This cohort study used aggregated electronic health records of US patients with early-onset AD and matched controls from January 1, 2004, through December 14, 2024, sourced from health care organizations in the collaborative research network TriNetX. Patients with early-onset AD and matched controls without AD were included in the analysis; those with uveitis prior to AD diagnosis were excluded. Propensity score matching was applied to balance baseline characteristics. The analyses were conducted on December 14, 2024.Exposure: International Classification of Diseases, 10th Revision (ICD-10) diagnosis code for AD.Main Outcomes and Measures: The primary outcome was the hazard ratio (HR) for developing pediatric uveitis in the AD cohort compared with the matched controls. Cox proportional hazards models were applied to assess the risk.Results: A total of 114 889 patients were identified in the AD cohort (mean [SD] follow-up, 6.0 [3.3] years; mean [SD] age, 0.5 [0.7] years; 64 817 male [56.4%]) and the control cohort (mean [SD] follow-up, 6.6 [3.7] years; mean [SD] age, 0.6 [0.8] years; 65 377 male [56.9%]) after matching. The AD cohort demonstrated a higher risk of developing pediatric uveitis compared with controls (94 [0.08%] vs 58 [0.05%]; HR, 1.92 [95% CI, 1.38-2.66]). Sensitivity analyses among patients without dupilumab use (89 of 113 284 [0.08%] vs 59 of 113 284 [0.05%]; HR, 1.77 [95% CI, 1.27-2.46]) and those without autoimmune conditions (80 of 114 425 [0.07%] vs 61 of 114 425 [0.05%]; HR, 1.52 [95% CI, 1.09-2.12]) similarly indicated an increased risk in the AD cohort. Additionally, patients with severe AD had a higher risk of developing pediatric uveitis compared with those with nonsevere AD (12 of 3004 [0.40%] vs 97 of 126 482 [0.08%]; HR, 3.64 [95% CI, 2.00-6.66]).Conclusions and Relevance: This cohort study of children with early-onset AD found an elevated risk of pediatric uveitis compared with matched controls, independent of autoimmune conditions or dupilumab use. These findings support the potential need to consider ophthalmologic monitoring in children with early-onset AD to try to detect and subsequently manage uveitis if it develops.


  • Adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema in Taiwan: a comparative cohort study

    by Wan-Ju Annabelle Lee, Shih-Chieh Shao, Miyuki Hsing-Chun Hsieh, Tzu-Chi Liao, Swu-Jane Lin, Edward Chia-Cheng Lai

    Aims To assess and compare the risk of adverse renal events among patients with diabetic macular oedema (DME) who were treated with either intravitreal ranibizumab or aflibercept in Taiwan. Methods We conducted a population-based retrospective cohort study and employed a target trial emulation framework using Taiwan’s National Health Insurance Database from 2011 to 2018. Patients aged over 20 years diagnosed with DME and receiving treatment with either intravitreal aflibercept or ranibizumab were included. We applied propensity score methods to ensure balance in the baseline characteristics between the two treatment groups. The primary outcomes were the adverse renal events, specifically acute renal injury and hospitalisation due to renal events. We employed Cox proportional hazards models to estimate the HRs associated with these outcomes. Results A total of 6330 patients receiving ranibizumab and 1258 patients receiving aflibercept were included in this study. The incidence rates of adverse renal events were 102.2 and 138.7 per 1000 person-years for ranibizumab and aflibercept, respectively. Patients treated with intravitreal aflibercept had a significantly higher risk of experiencing a composite of adverse renal events (HR: 1.42; 95% CI: 1.24 to 1.63), compared with those treated with ranibizumab, and specifically also a higher risk of acute kidney injury (HR: 1.32; 95% CI: 1.08 to 1.63) and hospitalisation due to renal events (HR: 1.43; 95% CI: 1.25 to 1.64). Conclusion In comparison to ranibizumab, the intravitreal use of aflibercept was associated with a greater risk of adverse renal events. These findings provide a solid foundation for future studies to validate these results further.


  • Eyelid Papilloma

    by Chun-Chieh Lai, Wan-Ju Annabelle Lee


  • Open Access

    Bilateral Optic Neuritis after COVID-19 Vaccination: A Case Report

    by Ching-Chih Liu, Wan-Ju Annabelle Lee

    Background: Neuro-ophthalmic manifestations after vaccines are rare, with optic neuritis (ON) being the most common presentation. Patients with vaccine-related ON are similar to those with idiopathic ON. The temporal relationship between vaccination against and the occurrence of ON is vital. Here, we report a case of bilateral ON after the administration of the ChAdOx1-S nCoV-19 SARS-CoV-2 vaccine. Case: A 49-year-old healthy Asian female presented with sudden onset of bilateral blurred vision within 2 days. She complained of photophobia and extraocular pain upon movement over 3 days. Upon examination, her best corrected visual acuity (BCVA) was 20/30 in the right eye and 20/200 in the left eye. Anterior segment findings were unremarkable, with normal intraocular pressure. Fundoscopic examination revealed bilateral disc edema with vessel engorgement. Visual field examination revealed profound visual field defect in both eyes. She denied any trauma, use of new medication or medical history. She had received the ChAdOx1 nCoV-19 SARS-CoV-2 vaccine 14 days prior. Under suspicion of vaccine-related optic neuritis, she was given intravenous methylprednisolone 1 gm/day for 3 days, shifting to oral prednisolone under gradual tapering for 2 weeks. Conclusions: Typically presenting with sudden-onset visual decline and extraocular pain during movement, acute ON is generally idiopathic. Bilateral ON is rare, but quick identification is important because it can potentially lead to permanent loss of vision if left untreated. Vaccination-induced ON is even rarer but not difficult to treat. However, such patients require further evaluation and long-term follow-up because they may be prone to other neurological disorders in the future.